Scholarlink

Purpose <p>To evaluate the safety and clinical effectiveness of transarterial embolization (TAE) using temporary embolic agents in patients with symptomatic hip osteoarthritis (OA) refractory to conservative treatment.</p> Materials and Methods <p>This single-centre retrospective analysis included patients undergoing TAE between January 2023 and April 2025. Eligibility required ≥ 3&#xa0;months of clinically and radiographically confirmed hip OA unresponsive to conservative therapy. Embolization was performed using rapidly resorbable gelatin microspheres or imipenem/cilastatin. Outcomes included technical success, adverse events, and patient-reported outcomes (numeric rating scale [NRS] pain; Hip Disability and Osteoarthritis Outcome Score [HOOS]) assessed at baseline and up to 12&#xa0;months. Clinically meaningful improvement was defined using minimum clinically important difference (MCID) thresholds (≥ 2 points for NRS; ≥ 10 points for HOOS).</p> Results <p>Forty-one patients (median age 65&#xa0;years) underwent TAE with a technical success rate of 97.5% (40/41). The lateral circumflex femoral artery was embolized in all cases, with additional internal iliac branches treated in 27.5% (11/40). No major or moderate adverse events occurred; minor transient skin discoloration was observed in 7.3% (all after imipenem/cilastatin). Median NRS decreased from 7 to 4 at 12&#xa0;months (<i>p</i> &lt; .001), with significant improvement across all HOOS domains. MCID was achieved in 64.3% for NRS and 85–92% for HOOS. Two patients (4.9%) underwent total hip replacement.</p> Conclusion <p>TAE using temporary embolic agents was associated with sustained pain reduction and functional improvement at 12&#xa0;months with a favourable safety profile.</p> Graphic Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transarterial Embolization for the Treatment of Symptomatic Hip Osteoarthritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月23日

查看全文
  • Florian Nima Fleckenstein,
  • Tazio Maleitzke,
  • Stephan Oehme,
  • Stefanie Donner,
  • Timo Alexander Auer,
  • Alexander Hildebrandt,
  • Carsten Perka,
  • Jens Vogel-Claussen,
  • Bernhard Gebauer,
  • Tobias Winkler,
  • Federico Collettini

摘要

Purpose

To evaluate the safety and clinical effectiveness of transarterial embolization (TAE) using temporary embolic agents in patients with symptomatic hip osteoarthritis (OA) refractory to conservative treatment.

Materials and Methods

This single-centre retrospective analysis included patients undergoing TAE between January 2023 and April 2025. Eligibility required ≥ 3 months of clinically and radiographically confirmed hip OA unresponsive to conservative therapy. Embolization was performed using rapidly resorbable gelatin microspheres or imipenem/cilastatin. Outcomes included technical success, adverse events, and patient-reported outcomes (numeric rating scale [NRS] pain; Hip Disability and Osteoarthritis Outcome Score [HOOS]) assessed at baseline and up to 12 months. Clinically meaningful improvement was defined using minimum clinically important difference (MCID) thresholds (≥ 2 points for NRS; ≥ 10 points for HOOS).

Results

Forty-one patients (median age 65 years) underwent TAE with a technical success rate of 97.5% (40/41). The lateral circumflex femoral artery was embolized in all cases, with additional internal iliac branches treated in 27.5% (11/40). No major or moderate adverse events occurred; minor transient skin discoloration was observed in 7.3% (all after imipenem/cilastatin). Median NRS decreased from 7 to 4 at 12 months (p < .001), with significant improvement across all HOOS domains. MCID was achieved in 64.3% for NRS and 85–92% for HOOS. Two patients (4.9%) underwent total hip replacement.

Conclusion

TAE using temporary embolic agents was associated with sustained pain reduction and functional improvement at 12 months with a favourable safety profile.

Graphic Abstract